



(11) **EP 1 997 506 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 38/08 ^(2006.01) **A61K 31/555** ^(2006.01)
A61K 33/24 ^(2006.01) **A61K 45/06** ^(2006.01)
A61P 35/00 ^(2006.01)

(48) Corrigendum issued on:
20.02.2013 Bulletin 2013/08

(86) International application number:
PCT/CU2007/000010

(45) Date of publication and mention
of the grant of the patent:
05.12.2012 Bulletin 2012/49

(87) International publication number:
WO 2007/098719 (07.09.2007 Gazette 2007/36)

(21) Application number: **07711104.5**

(22) Date of filing: **28.02.2007**

(54) **USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS**

VERWENDUNG EINES CK2-HEMMERS ZUR BEHANDLUNG UND CHEMOSENSIBILISIERUNG VON REFRAKTÄREN TUMOREN GEGEN ANTI-KREBS-MITTEL

COMBINAISON PHARMACEUTIQUE POUR LE TRAITEMENT ET/OU LA CHIMIOSENSIBILISATION DE TUMEURS RÉFRACTAIRES AUX MÉDICAMENTS ANTICANCÉRIGÈNES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **28.02.2006 CU 492006**

(43) Date of publication of application:
03.12.2008 Bulletin 2008/49

(73) Proprietors:
• **CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA**
Ciudad de La Habana 10600 (CU)
• **Biorec S.A.**
Montevideo 11.000 (UY)

(72) Inventors:
• **PEREA RODRÍGUEZ, Silvio, Ernesto**
Ciudad De La Habana 10 600 (CU)
• **PERERA NEGRÍN, Yasser**
La Habana 32 600 (CU)
• **RODRÍGUEZ ULLOA, Arielis**
La Habana 33 500 (CU)

- **GIL VALDÉS, Jeovanis**
Rpto. Eléctrico, A. Naranjo;
Ciudad De La Habana 10 900 (CU)
- **RAMOS GÓMEZ, Yassel**
Boyeros
Ciudad De La Habana 19 290 (CU)
- **CASTELLANOS SERRA, Lila, Rosa**
Ciudad De La Habana 10 600 (CU)
- **BETANCOURT NÚÑEZ, Lázaro, Hiram**
Ciudad De La Habana 12 500 (CU)
- **SÁNCHEZ PUENTE, Aniel**
Ciudad De La Habana 12 500 (CU)
- **FERNÁNDEZ DE COSSIO DORTA DUQUE, Jorge**
Ciudad De La Habana 11 300 (CU)
- **ACEVEDO CASTRO, Boris, Ernesto**
Ciudad De La Habana 10 600 (CU)
- **GONZÁLEZ LÓPEZ, Luis, Javier**
Ciudad De La Habana 10 600 (CU)
- **BESADA PÉREZ, Vladimir**
Ciudad De La Habana 19 140 (CU)
- **ALONSO, Daniel, Fernando**
Buenos Aires, 1886 (AR)
- **GOMEZ, Daniel, Eduardo**
Buenos Aires, 1876 (AR)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 997 506 B8

(74) Representative: **Hatzmann, Martin et al**
Vereenigde
Johan de Wittlaan 7
2517 JR Den Haag (NL)

(56) References cited:
EP-A- 1 491 553 WO-A1-2005/056014

- **PEREA S E ET AL: "Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2)" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, 1 October 2004 (2004-10-01), pages 7127-7129, XP002399575 ISSN: 0008-5472 cited in the application**

- **PIAZZA F. ET AL.: "Multiple myeloma cells survival and proliferation rely on high levels and activity of the serine-threonine kinase CK2." BLOOD, vol. 104, no. 11, 16 November 2004 (2004-11-16), page 186A, XP009086788**
- **SARNOS. ET AL.: "Development and exploitation of CK2 inhibitors." MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 274, 2005, pages 69-76, XP019288786**